GRI Bio Inc (GRI)
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for inflammatory, fibrotic, and autoimmune disorders in the United States. The company’s lead candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T cells and is being evaluated in a phase IIa trial for severe fibrotic lung diseases, including idiopathic pulmonary fibrosis. Its pipeline also includes GRI-0803, an oral type 2 Natural Killer T-cell agonist in preclinical development for autoimmune disorders, along with GRI-0124 and GRI-0729, which are intended to help balance inflammatory immune responses. GRI Bio also maintains a proprietary library of more than 500 compounds. The company, formerly known as Glycoregimmune, Inc., was founded in 2009 and is headquartered in La Jolla, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GRI
|
$2.02
|
34.0% Upside
|
Undervalued
|
$21 1,295.3% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-0.2x
|
0.3x
|
—
|
2.603 M
|
-8.325 M
|
2.2%
|
100.0%
|
1.3
|
—
|
111.3%
|
